Article Information
History
- June 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Kei Nakashimaa,*,
- Masayuki Ishidab,
- Hiroyuki Matsuic,
- Chihiro Yoshidaa,
- Tatsuya Nagaia,
- Minoru Shiragab,
- Hiroshi Nakaokab,
- Yoshihito Otsukad,
- Yu Nakagamae,
- Natsuko Kakue,
- Yuko Nitaharae,
- Yasutoshi Kidoe and
- Yoshio Hirotaf
- aDepartment of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
- bDepartment of Pulmonology, Chikamori Hospital, 1-16 Okawasuji, Kochi, 780-8522, Japan
- cClinical Research Support Office, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
- dDepartment of Laboratory medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
- eDepartment of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
- fClinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), 3-5-1 Kashii-Teriha, Higashi-ku, Fukuoka, 813-0017 Japan
- ↵*Corresponding author
Kei Nakashima, Department of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan, Tel: +81 4 7092 2211, Fax: +81 4 7092 1198, Email: kei.7.nakashima{at}gmail.com
Posted June 26, 2022.
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
